One-in-a-million people are living with EHE worldwide.

Our mission is to find treatments and a cure for epithelioid hemangioendothelioma (EHE) by advancing research and driving collaboration among patients, researchers, and clinicians.

We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.

Patient-Powered EHE Research

EHE Biobank

Patients are the key to finding new treatments for EHE! Researchers need tumor tissue and fluid from EHE patients to understand disease progression and speed the development of new drugs and therapies.

EHE Global Patient Registry

The EHE Global Patient Registry empowers people with Epithelioid Hemangioendothelioma (EHE) to join together to improve our understanding of this ultra-rare sarcoma. We need every EHE patient to join this critical tool used to support researchers searching for treatments and a cure for EHE.

Latest EHE News, Events and Research

Scientific & Medical Advisory Board Collaborates to Improve Outcomes for People Living with EHE

By EHE Foundation | October 1, 2024

On September 10, 2024, The EHE Foundation held a virtual meeting of our Scientific & Medical Advisory Board (SMAB). The meeting aimed to welcome new members, review current research projects, and discuss future needs and goals to advance EHE research. The meeting began with a warm welcome to new members of the SMAB: Tom Chen, […]

GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and is Down-regulated by Sirolimus Through ATF4/ATF5 Suppression

By EHE Foundation | September 27, 2024

Drs. Silvia Stacchiotti, Sandro Pasquali, and Nadia Zaffaroni (IRCCS – INT, Milan, Italy) and colleagues published their promising findings in Clinical Cancer Research, September 16, 2024. This study, funded in part by The EHE Foundation in partnership with EHE Rare Cancer Charity (UK), aimed to assess the efficacy of sirolimus for the treatment of EHE […]

Harnessing Cyclin-dependent Kinase Inhibitors to Gain Mechanistic Insight Into the Regulation of the TAZ-CAMTA1 Fusion Protein

By EHE Foundation | September 23, 2024

Ajay Pobbati, PhD, Brian Rubin, MD, PhD, and colleagues at the Cleveland Clinic published their findings from the study “CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma” in Clinical Cancer Research, September 13, 2024. This study, funded in part by a grant from The EHE Foundation, provides a strong rationale for investigating […]

EHE Community Connections for Caregivers: Anticipatory Grief

By EHE Foundation | September 9, 2024

As a caregiver, it can be hard to not think about the future and what it may or may not hold. In doing so, it is common for caregivers to experience anticipatory grief, in which we mourn the loss of our loved one while they are still here as well as grieve the future that […]

The EHE Foundation Appoints New Executive Director

By EHE Foundation | August 14, 2024

On behalf of the Board of Directors of The EHE Foundation, Jenni Kovach, Board President has announced the appointment of Denise Robinson as the new Executive Director for the Foundation.  Like many people, Denise had not heard of EHE until her friend was diagnosed in 2017 with an aggressive form of the disease. She soon […]

The Pledge: Edition 37, Q2 – April-June, 2024

By EHE Foundation | August 8, 2024

Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe. provide content including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of our online EHE newsletter, The Pledge.

EHE Foundation Awards $335,000 in New Research Grants to Advance Progress in EHE

By EHE Foundation | March 16, 2026

The EHE Foundation is proud to announce $335,000 in funding through the 2026 EHE Foundation Research Grants Program to support two innovative research projects in epithelioid hemangioendothelioma (EHE). Selected for their scientific merit, potential impact, and clinical relevance, these projects address two important priorities in EHE research: biomarker development and new therapeutic approaches. Together, they […]

The Pledge: Edition 43, Q4 – October-December, 2025

By EHE Foundation | February 15, 2026

Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe provide content, including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of the online EHE newsletter, The Pledge.

Understanding Quality of Life for People Living With EHE

By Kristianne Oristian, PhD | February 10, 2026

The European Organisation of Research and Treatment of Cancer (EORTC) is conducting research to better understand health-related quality of life (HRQoL) concerns among people living with rare cancers. Recently, researchers analyzed results from a group of 31 people with EHE from 11 different countries who participated in the study. The findings showed that pain–and the […]